Heather Munoz discusses how blood center infrastructure and flexible collection models are supporting the continued growth of cell and gene therapy.
Heather Munoz, principal, global market development at BBG Advanced Therapies, is featured in a recent Technology Networks article examining the expanding role of blood centers in advancing cell and gene therapy.
The article explores how blood centers are uniquely positioned to support advanced therapies through established donor management infrastructure, specialized starting material collections and nationwide logistics capabilities. As demand for autologous and allogeneic cell therapy starting materials continues to grow, blood centers are increasingly serving as critical partners in ensuring reliable, patient-centered access to transformative treatments.
“As a nurse, I’ve seen firsthand how access and timing shape both outcomes and hope. Access is personal,” Munoz said. “Blood centers have the trusted relationships and nationwide reach to bring cell and gene therapies closer to patients — without compromising quality or compliance.”
In the piece, Munoz discusses the importance of flexible collection models that meet patients where they are — whether through inpatient hospital collections, outpatient procedures at blood centers or mobile collections at rural oncology clinics. She emphasizes that scalable, compliant collection strategies are essential to expanding equitable access to cell and gene therapies.
